Synthetic Biologics (NYSEAMERICAN:SYN) Trading 1% Higher

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) traded up 1% on Monday . The company traded as high as $1.02 and last traded at $1.02. 57,700 shares traded hands during trading, a decline of 71% from the average session volume of 197,338 shares. The stock had previously closed at $1.01.

Synthetic Biologics Stock Up 1.0 %

The firm has a market cap of $16.16 million, a price-to-earnings ratio of -0.84 and a beta of 1.38.

Hedge Funds Weigh In On Synthetic Biologics

Several institutional investors and hedge funds have recently bought and sold shares of SYN. Jane Street Group LLC bought a new stake in shares of Synthetic Biologics in the 1st quarter worth approximately $80,000. Renaissance Technologies LLC grew its position in shares of Synthetic Biologics by 103.9% in the 2nd quarter. Renaissance Technologies LLC now owns 219,000 shares of the company’s stock worth $47,000 after buying an additional 111,600 shares during the last quarter. Northern Trust Corp grew its position in shares of Synthetic Biologics by 37.1% in the 1st quarter. Northern Trust Corp now owns 336,399 shares of the company’s stock worth $96,000 after buying an additional 91,000 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Synthetic Biologics in the 3rd quarter worth approximately $55,000. Finally, Vanguard Group Inc. grew its position in shares of Synthetic Biologics by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 5,296,501 shares of the company’s stock worth $1,511,000 after buying an additional 48,102 shares during the last quarter. 74.38% of the stock is currently owned by institutional investors.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.